disease, which may be associated with toxicants that are metabolized via a NQO1-dependent pathway.
metabolism, but it can also be mediated by colonocytes of the Spain and 6 Laboratory for Molecular Epidemiology, Department of intestinal tract and may play a role in colorectal cancer (CRC) Epidemiology and Biostatistics, School of Medicine, University of (1). Among the enzymes present in the intestinal mucosa, California San Francisco, San Francisco, CA 94143-0560, USA NAD(P)H:quinone oxidoreductase (NQO1) (EC 1.6.99.2) 7 To whom correspondence should be addressed carries out the two electron reduction of potentially toxic Email: alafuente@med.ub.es quinones (2), which are ubiquitous in aerobic plants and
NAD(P)H:quinone oxidoreductase (NQO1) is a poly-
animals and are present in the environment as combustion morphic enzyme involved in the detoxification of potentially by-products (e.g. automobile exhaust, cigarette smoke and mutagenic and carcinogenic quinones. The homozygous urban airborne particles) (3,4). Diet can also be an indirect C609T NQO1 genotype resulting in loss of reductase activity source of exposure to these compounds as some prois found in 2-20% of individuals. In the present study, the carcinogens present in food, such as benzo [a] pyrene (BP),
NQO1-dependent risk for sporadic colorectal cancer (CRC)
can be metabolized in cells to quinone intermediates. Because was studied in 247 incident CRC cases and 296 hospitalof their electrophilic nature and very high redox potential, based controls recruited during 1996-1997. Four subgroups quinones can be highly toxic. Indeed several compounds of cases were studied: (i) all CRCs; (ii) a molecular CRC containing the quinone nucleus are extensively used as cytosubgroup (n ⍧ 117, cases with molecular tumor analyses); toxic antitumor drugs (5). The mechanisms underlying the (iii) within the molecular subgroup those tumors with toxicity of quinones, particularly those important in CRC K-ras mutations in codon 12 (CRC K12); (iv) within the carcinogenesis and which are under genetic control, are poorly molecular subgroup those tumors with K-ras mutations in understood.
codon 13 (CRC K13). The C609T NQO1 genotype was
Recently, a genetic polymorphism in NQO1 involving a found to be twice as prevalent in all CRC patients (6.8%)
C→T nucleotide substitution at base pair 609 has been identicompared with controls (3%) and six times more common fied (6), which in homozygous form is associated with nonin the subset CRC K12 (20%). Multivariant analyses in detectable NQO1 activity (7,8);~2-20% of individuals carry the overall population of 247 cases and 296 controls the C609T NQO1 genotype (9). The prevalence of the low showed a significant age and gender adjusted risk for CRC activity allele is highest among Asians and lowest in European associated with the C609T NQO1 genotype (OR 2.9, 95% populations (9-11). NQO1 has been implicated in lung CI 1.19-6.97; P ⍧ 0.01) or with any variant genotype cancer (10, 12, 13), benzene poisoning (14), leukemia (15,16), (the low activity allele frequency, i.e. heterozygotes plus cutaneous basal cell carcinoma (17) and urological malignanhomozygotes) (OR 1.41, 95% CI 1.02-1.92; P ⍧ 0.03).
cies (18) . In vitro, the formation of DNA adducts by quinone Within cases of the molecular subgroup (n ⍧ 117) the metabolites of BP (BPQs) (19) and benzene (20) have been C609T NQO1 genotype was associated with the presence shown to be significantly reduced by NQO1 activity. In of K-ras codon 12 mutation (OR 6.5 95%, CI 1.39-34.9; addition, NQO1 is also involved in the activation of vitamin P ⍧ 0.003). Logistic regression showed an age and gender K, which is a potent antioxidant (21) and has antimutagenic adjusted risk for K-ras codon 12 mutant CRC associated effects against genotoxic heterocyclic amines from cooked with the C609T NQO1 genotype (OR 10.5, 95% CI 2.99-food (22) . For these reasons we have examined NQO1 as a 36.7; P ⍧ 0.0002) or with any variant NQO1 genotype candidate susceptibility locus for sporadic CRC in the present (OR 2.23, 95% CI 1.23-4.00; P ⍧ 0.007) compared with hospital-based case-control study. the control group. Genetically determined variations in Because genetic susceptibility involving altered quinone NQO1 may modify the risk for CRC and these risks may metabolism may influence risk for specific molecular subtypes be greatest for tumors containing K-ras codon 12 mutations.
of CRC, we examined the potential associations of NQO1 CRC with K-ras codon 12 mutations may represent a with mutations in the K-ras gene within a subset of CRC distinct and etiologically more homogeneous subtype of the cases whose tumors were collected at surgery. The K-ras gene encodes a protein (p21 ras ) belonging to a family of GTP/GDP- (27) . An aliquot of 2 µl of the first round PCR product sporadic CRC patients undergoing surgery were identified through the Clinic's was added to the second round PCR (100 µl volume) and amplified with two surgical services as potential subjects for a hospital-based case-control either a screening primer (sense) for codon 12 (5Ј-ACTGAATATAAAstudy of CRC. Patients who were ജ40 and Ͻ90 years old were invited to CTTGTGGTAGTTGGACCT-3Ј) or for codon 13 (5Ј-CTGAATATAAACparticipate in the study. Eighteen subjects refused to participate, leaving a TTGTGGTAGTTCCAGCTGGT-3Ј). The same antisense primer as used in final total of 247 enrolled Caucasian subjects (131 men and 116 women). A the first round PCR was used for both codon 12 and 13 screening. PCR was consecutive case series subset of 117 patients (originally 120, but three patients repeated for 35 cycles using the following conditions: 94°C for 30 s, 55°C were older than 90) within one surgical service also provided tissue specimens for 30 s, 72°C for 30 s, with a final extension at 72°C for 10 min. After PCR, (uninvolved colon and tumor) for the molecular study. The remainder of the 16 µl of the second round PCR product was digested with either BstNI (codon CRC group only provided blood samples. Primary tumors were surgically 12) or Pflm1 (codon 13) for 4 h. Digests were analyzed using 3.5% agarose dissected and immediately frozen at -80°C. Patients gave their signed informed gels. PCR products resistant to enzyme digestion indicated the presence of a consent; all procedures were approved by the Ethical Research Board of the base pair substitution. For each set of samples a positive control DNA Hospital Clinic. A questionnaire was administered to each patient by an (SW480) containing a codon 12 mutation was also run to provide quality interviewer; the questionnaire elicited demographic information, data on control on the amplification and restriction enzyme digestion. After tumors occupation and smoking habits and personal medical history. The primary were identified as having a mutation in codon 12 or 13 they were analyzed measure of smoking was the pack year unit (pack year ϭ number of packets using the human ras MUTALYZER probe panel and dot-blot hybridization of 20 cigarettes per dayϫnumber of years). Clinical and pathological data according to the manufacturer's instructions (Clontech, Palo Alto, CA). If the were collected and merged with patient questionnaires. No cases reported a products were very strong, they were sequenced directly. For direct sequencing, positive family history of early onset CRC or multiple familial cases that the second round products were gel purified (Qiagen, Valencia, CA) and might indicate an inherited dominant CRC gene. A modified version of Duke's sequenced with the antisense primer using an ABI 373 automated sequencer. staging system was used. Surgical records identified eight subsites: cecum,
To confirm the accuracy of the dot-blot results, a total of 31 samples were ascending colon, transverse colon, descending colon, sigmoid colon, directly sequenced and dot-blotted. rectosigmoid junction, rectum and anal canal. Proximal tumors were defined Statistical analyses as including the right side of the colon and descending colon up to the Data were analyzed using SPSS 6.1.2 (statistical analysis software). Means sigmoid colon.
and standard deviations were computed for continuous variables. Age-adjusted The control group consisted of consecutively recruited patients presenting univariate analysis was employed to identify environmental factors associated to the Trauma service of the Hospital Clinic during the same time period as with CRC and CRC with K-ras mutations. Univariate analysis also tested for case accrual. This service deals with~2000 admissions/year of patients living associations of NQO1 genotypes with either the risk of CRC or CRC with in the same metropolitan area (Barcelona) as the cases studied. To facilitate specific K-ras mutations. Multivariate analyses (multiple logistic regression) sampling, patients whose pre-operatory study (including blood analysis) was were used to estimate the independent contribution of each variable identified performed in the outcare service were excluded. Only patients between ജ40 though univariate analysis to the risk of CRC and CRC with K-ras mutations. and Ͻ90 years old were invited to participate in the study, following the same Confidence limits for the adjusted odds ratio were calculated with the procedure as for cases. The same epidemiological data and blood samples associated logistic coefficients and standard errors. were collected from controls as was done for cases. Most of the control group were admitted for articular hip or knee replacement, pelvis fracture or injury to upper or lower ribs. Controls were excluded if they reported a history of Results malignancy. Table I shows the characteristics of CRC patient and control DNA was isolated from blood and tumor specimens using standard methods employing RNase, proteinase K and chloroform/isoamyl alcohol extraction groups. The subset of patients for whom tumor tissue was and ethanol precipitation. DNA was quantified by Hoescht 33258 fluorimetry available (molecular CRC group) was very similar to the (Hoefer Scientific, San Francisco, CA). All analyses were carried out on overall CRC group in terms of age, sex and smoking patterns. coded samples and the analyst was blind to the case/control status.
There were more male cases than females in both case groups; NQO1 polymorphism the distribution of the sexes was identical to the 53% males
In the PCR analysis the sense (5Ј-TCCTCAGAG TGGCATTCTGC-3Ј) and antisense primers (5Ј-TCTCCTCATCCTGTACCTCT-3Ј) amplify a 211 bp region including the last 7 bases of exon 5 and the first 204 bases of intron 6 (25) . PCR reactions were carried out in a 30 µl volume of 30 mM Tris- tumors (all CRC 79.4%; molecular CRC 93.1%) and women aged Ͼ70 years presented with proximal tumors in 46.5 and 62.5% of cases within the overall CRC and molecular CRC clinical variables and to compare the overall and molecular groups we show in Table III the distribution of C609T NQO1 groups, respectively. K-ras mutations were observed in 41.8% of all cases; these genotypes among CRC patients according to several clinical characteristics. The data do not suggest an association of were located in codon 12 in 29.9% of patients and in codon 13 in 11.9% of patients (Table II) . Although the prevalence of genotype with stage, differentiation or location of the tumor. Considering the small number of cases in some of the sub-K-ras mutations was higher in men than in women (34.4 versus 25% mutant at codon 12), the difference was not groups, the range in prevalence of the C609T NQO1 genotype by these variables in the overall CRC group (5.2-11.7%) was statistically significant. Poorly differentiated tumors had roughly half the number of codon 12 mutations compared with similar to that of the molecular CRC group (5.8-16.6%). Table IV shows the distribution of the C609T NQO1 moderate or well-differentiated tumors, but again the difference was not statistically significant.
genotype in the different subgroups studied: controls, all CRC, molecular CRC, molecular CRC patients with K-ras mutations To explore potential associations of NQO1 genotype with in codon 12 (CRC K12) and molecular CRC patients with K-ras compared with heterozygous and wild-type individuals. In this model the C609T NQO1 genotype was associated with CRC mutations in codon 13 (CRC K13). The overall prevalence of the C609T NQO1 genotype in the control group was 3% and case status in comparisons, including all patients (OR 2.9, 95% CI 1.19-6.97), only with the subgroup who had K-ras the low activity allele frequency was 20.1%. There were no apparent differences in the prevalence of these genotypes when codon 12 mutations (OR 10.52, 95% CI 2.99-36.7) or with the subgroup who had any K-ras mutation (codon 12 or 13) the group was divided into different age and sex strata. Although non-smokers had a higher percentage of the homo-(OR 5.92, 95% CI 1.88-18.2). In Model 2 of the logistic analyses we considered NQO1 as a dominant trait and comzygous mutated genotype (3.6%) than smokers (smokers plus former smokers 1.9%), these differences were non-significant. pared the homozygous and heterozygous individuals with wildtype individuals. Lower but statistically significant risks were Hence, within controls no associations were indicated between the C609T NQO1 genotype and age, gender or smoking.The associated with carrying one or two NQO1 variant alleles, including: all patients (low activity allele frequency, OR 1.41, C609T NQO1 genotype was found to be twice as prevalent in CRC patients (6.8%) compared with controls (3%) and six 95% CI 1.02-1.92), only cases with K-ras codon 12 mutations (OR 2.23, 95% CI 1.23-4.00,) or cases with any K-ras times greater in the subset CRC K12 (20%). The low activity allele frequency was 24.2% in the CRC group, 28.2% in the mutations (codon 12 or 13) (OR 2.12, 95%CI 1.27-3.52). Non-significant interactions were observed between NQO1 molecular CRC group and increased to 34.2% in the subgroup CRC K12; unadjusted odds ratio (OR) for the C609T NQO1
and sex in both Models 1 and 2. Similar results were obtained in models that included cigarette smoking and not gender genotype and case status was 2.36 [95% confidence interval (CI) 097-5.84]. When the groups were stratified by gender a (including a non-significant interaction between NQO1 and smoking), however, because the overwhelming number of significant risk was observed in women (OR 3.13, 95% CI 1.03-9.80), while in men a lower point estimate was not smokers were men it was not possible to separate out the effects of male gender and smoking. Small sample sizes significant (OR 1.73, 95% CI 0.37-8.96). In addition, within cases there was a positive but non-significant association of precluded stratified analyses of smoking within women or men alone. K-ras mutation (either codon 12 or 13) with the C609T NQO1 genotype (OR 3.47, 95% CI 0.75-18.09), however, there was
Other demographic and socioeconomic factors were examined. We tested the potential association of case status with a significant association of the C609T NQO1 genotype with K-ras codon 12 mutation (OR 6.58, 95% CI 1.39-34.9).
low physical activity, female reproductive history (menopause or total time of fertility, parity or age at first birth), urban versus Because of the unbalanced gender and age distribution of the controls it is especially important to adjust for these factors.
rural residence, years of formal education and current marital status; none of these variables approached statistical significance In addition, smoking was considered a potential confounder but was so strongly associated with male gender that it was in any model. Moreover, no significant association was found between smoking and risk of CRC in males (results not shown). analyzed in models without gender.
Summarized results on the multivariate analysis including To provide a descriptive presentation of the mutational spectra of K-ras within this group of Spanish CRC patients, age and gender are shown in Table V . In Model 1 NQO1 is considered a recessive trait so that homozygous variants are we summarized the results of the sequencing data for the a Controls versus CRC with K-ras mutations in either codon 12 or 13. Model 1 was a multivariant analysis that studied the NQO1 genotype in two categories and adjusted by age and sex: homozygous C609T NQO1 genotype versus heterozygous and homozygous wild-type genotype. Model 2 studied the NQO1 low activity allele considered as a continuous variable (0, wild-type; 1, heterozygous; 2, homozygous mutated) and adjusted by age and sex. No significant interactions were observed between NQO1 and sex in either Model 1 or 2. molecular CRC group (Table VI) . The most common mutation the NQO1 genotype could be associated with features of the control group that arise as a consequence of our method of in K-ras results in a Gly→Asp amino acid substitution: 48.4% in codon 12, 100% in codon 13. Mutations leading to Gly→Val enrollment. We did not find evidence that the control was biased with respect to the NQO1 gene. First, the prevalence substitutions were the second most common mutation. Transitions from G to A occurred in 68% of mutations seen either of the C609T NQO1 genotype and allele frequencies in controls, although lower than ethnic groups within the USA, in codon 12 or 13, transversions of G to T in 27.6% and G to C in only 4.2%. There was no evidence of a trend towards a was very consistent with multiple reports from Europe and the UK. For example, we observed a prevalence of 3% C609T specific mutation pattern in smokers.
NQO1 genotypes among our 296 controls; studies in Germany reported a 1.5% (n ϭ 271) (11) and 2.0% (n ϭ 100) (29) Discussion prevalence, whereas in the UK the prevalence is 1% (n ϭ Although the base pair alteration leading to loss of enzymatic 100) (15) and in French Caucasians 3.8% (n ϭ 210) (30) ; the activity of NQO1 was first discovered within a CRC cell line frequency of the low activity allele in the DNA bank of the and later identified as a common polymorphism, the potential Center d'Etude Polymorphisme Humain was 13% (n ϭ 82) risk associated with this allele for CRC has not been studied.
(10). Also important is our failure to observe an association In the present investigation we genotyped a relatively large of the NQO1 genotype with gender, age or smoking status number of incident CRC cases from a single institution and in controls. Although other unidentified risk factors could found these patients to have a higher prevalence of the NQO1 potentially bias our study, we examined demographic, sociolow activity allele (both as homozygous and heterozygous economic and reproductive factors and did not observe any traits) compared with a control group selected concurrently significant difference in these indices between cases and from the Trauma service of the same hospital. Also, the controls. Finally, there is no evidence that the primary medical association was significant in stratified analyses considering conditions affecting controls from the Trauma service are only women in the study. In interpreting our results it is associated with genetic variations at the NQO1 locus. Specificimportant to note that our choice of method for control ally, fractures, hip replacements and other orthopedic conditions selection, although economical, has some drawbacks. The have no known or hypothesized connection with quinone control group from the Trauma service was somewhat younger metabolism or NQO1. Hence, we conclude that our control than the cases and contained relatively more women (62.5%) group is unlikely to be biased in terms of its genetic background than the case group (46.9%). Overall, smoking was more and distribution of NQO1 genotypes, which is the primary common in female controls than in female cases. The rates of focus of this research. smoking were similar among male cases and controls. Consist-
The clinical-pathological characteristics of our CRC group ent with the base population in Catalonia, rates of smoking are similar to those reported in a recent population-based were markedly higher in men compared with women (cases case-control study in Majorca, Spain (31) and for other and controls). The importance of differences in smoking rates series (32, 33) . in interpreting the observed association of NQO1 in cases and
The association between the C609T NQO1 polymorphism controls is not entirely clear, as smoking has only inconsistently and CRC risk is clear, especially for CRC with a mutation in been implicated as a risk factor for CRC (28) . It was a codon 12 (no association was evident for K-ras codon 13), secondary aim of the study, however, to examine possible but it weakens when the frequency of the low activity allele relationships of smoking history with K-ras mutations, given is studied. Therefore, toxicological consequences of this polythat tobacco has been linked with K-ras in other cancers (e.g. morphism seem especially relevant in homozygous individuals lung cancer). Nonetheless, a primary consideration is whether when there is complete lack of NQO1 activity. Codon 12 is the predominant target for mutations in K-ras in CRC, here accounting for 70% of the observed alterations. This is similar genicity of quinone metabolites of BP (BPQs), the mutational GGT (Gly)→GCT (Ala) 2/2 (100%) spectra of these compounds included G→T transversions, as a Number of cases with this mutation/all (%).
does that of BP diol epoxide, but G→A transitions were also b Number of cases with this mutation who smoked/all (%).
detected (38 factors, such as smoking and alcohol consumption, with a specific K-ras mutation pattern in pancreatic tumors (39, 40) , agents such as Oltipraz and other dithiol-3-thiones, indoles and isothiocyanates may exert their protective effects against but evidence is still scant and inconsistent. In other cancers, the relationship of smoking with K-ras has not been established toxicity, mutagenesis and carcinogenesis through their induction of NQO1 activity (49). A note of caution is also indicated (41-43). In our study, K-ras mutations were almost equally common in tumors from men and women, although the rates from our studies as genetic deficiency affecting the NQO1 locus may increase CRC risk and mitigate against such of cigarette smoking were much greater in men. This would tend to indicate that smoking may not be involved in the pharmacological strategies; the C609T NQO1 genotype precludes any benefit that might derive from treatment with induction of K-ras, but we did not have a sufficient sample size to address this question adequately nor did we collect inducers of reductase activity, and alternative interventions for genetically susceptible individuals may be needed. information on lifetime exposure to environmental tobacco smoke in women, which may have been significant. Anecdotally, we noted that all four C609T NQO1 genotypes from patients who reported being smokers or former smokers hadferases or be reduced to CE by quinone reductase. If these and xenobiotic quinones and should be studied further for its and Greaves,M.F. (1999) A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that potential to prevent human cancer. Indeed, chemopreventive
